Predictive immune markers in advanced melanoma patients treated with ipilimumab

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Umansky, Viktor ^a   Utikal, Jochen ^a   Gebhardt, Christoffer ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Eosinophils; HMGB1; ipilimumab; melanoma; myeloid derived suppressor cells; predictive markers; S100A8 A9

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IPILIMUMAB; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROGRAMMED DEATH 1 RECEPTOR; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER GROWTH; DISEASE COURSE; DOWN REGULATION; EOSINOPHIL; HUMAN; IMMUNOMODULATION; MELANOMA; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SUPPRESSOR CELL;

EID: 84976592937     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1158901     Document Type: Article

References (10)

1. S.Stadler, K.Weina, C.Gebhardt, J.Utikal. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 2015; 60:83-8; PMID:25596540; 10.1016/j.advms.2014.12.002
2. V.Umansky, A.Sevko, C.Gebhardt, J.Utikal. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges 2014; 12:1021-7; PMID:25263083; 10.1111/ddg.12411
3. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; 10.1038/nri3175
4. J.Kanterman, M.Sade-Feldman, M.Baniyash. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012; 22:307-18; PMID:22387003; 10.1016/j.semcancer.2012.02.008
5. V.Umansky, A.Sevko. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319-26; PMID:22349515; 10.1016/j.semcancer.2012.02.003
6. S.Ostrand-Rosenberg, P.Sinha. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; 10.4049/jimmunol.0802740
7. P.Altevogt, N.P.Bretz, J.Ridinger, J.Utikal, V.Umansky. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin Cancer Biol 2014; 28:51-7; PMID:24769223; 10.1016/j.semcancer.2014.04.008
8. H.Jiang, C.Gebhardt, L.Umansky, P.Beckhove, T.J.Schulze, J.Utikal, V.Umansky. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 2015; 136:2352-60; PMID:25353097; 10.1002/ijc.29297
9. C.Gebhardt, A.Sevko, H.Jiang, R.Lichtenberger, M.Reith, K.Tarnanidis, T.Holland-Letz, L.Umansky, P.Beckhove, A.Sucker et al. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res 2015; 21:5453-9; PMID:26289067; 10.1158/1078-0432.CCR-15-0676
10. M.Z.Noman, G.Desantis, B.Janji, M.Hasmim, S.Karray, P.Dessen, V.Bronte, S.Chouaib. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; 10.1084/jem.20131916